| Literature DB >> 33160678 |
Jancy Johnson1, Yu-Wen Wu2, Chantelle Blyth3, Gregor Lichtfuss1, Hadi Goubran4, Thierry Burnouf5.
Abstract
There is much interest in the use of extracellular vesicles (EVs) as a subcellular therapy for regenerative medicine and drug delivery. Blood-borne platelets represent a source of therapeutic EVs that is so far largely unexplored. Advantages of platelets as a cellular source of EVs include their established clinical value, regulated collection procedures, availability in a concentrated form, propensity to generate EVs, and unique composition and tissue-targeting capacity. This review analyzes the unique potential of platelet-derived (p-) EVs as therapeutic modalities and presents their inherent translational advantages for hemostasis, for regenerative medicine, and as drug-delivery vehicles.Keywords: drug delivery; exosome; extracellular vesicle; platelet; regeneration
Year: 2020 PMID: 33160678 DOI: 10.1016/j.tibtech.2020.10.004
Source DB: PubMed Journal: Trends Biotechnol ISSN: 0167-7799 Impact factor: 19.536